I understood it perfectly. As an investor, to me this looks like: another study completed, no signs of contracts signed, more studies are coming (how many more?). No sign of when this study will turn into cash flow. No sign of how this study fits in the business model.
PIQ needs to understand it is a business, not a science experiment. Businesses need to generate cash flow, not studies alone. If Businesses are yet to generate cash flows, they need to understand how they will generate that cash flow, and convey that to it's shareholders.
This upcoming quarterly will likely show no income from PromarkerD yet again, even though supposedly deals have been signed with various jurisdictions. One must be asking why is that?
Harsh, but in business there is no room for the faint hearted.
PIQ Price at posting:
$1.03 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)